Melvin LK CHUA, Clinician-Scientist at the NCCS and Duke-NUS Medical School, shared a post on X:
“Interesting poll from Nasopharyngeal Carcinoma.
Meeting in Guangzhou among Chinese Experte.
What should be the SOC for high-risk NPC trial?
In case translation is needed, option 1 is IC+CRT and option 2 is IC+CRT+Cap.”
More posts featuring Melvin LK CHUA on OncoDaily.
